The present invention provides compounds of formula I, and pharmaceutically acceptable salts and solvates thereof. The compounds are useful as pharmaceuticals and are particularly useful in the treatment of fibrotic diseases, cancer and pain. Wherein R 1 represents a cyclic group selected from phenyl, heteroaryl 1, heterocyclyl 1 and C 3 -C 6 cycloalkyl, wherein each cyclic group is halo, 1 to 3 halogen atoms. 1 to 3 substituents selected from C1-C6 alkyl, phenyl, optionally substituted with 1 to 3 halogen atoms, optionally substituted with C1-C6 alkoxy, cyano, heteroaryl 1a and heterocyclyl 1a Wherein each cyclic group is selected from a benzene ring or a 5- or 6-membered heteroaromatic or heterocyclic ring (each selected from 1 to 3 heteroatoms (N, O and S) ), Optionally substituted, and each cyclic group is substituted, the substitution can generally occur anywhere in any fused ring system, and can be heterocyclyl 1 and hete Cyclyl 1a may be additionally substituted with ═O, X represents a bond or C1-C6 alkylene (which may be linear or branched), R2 represents H or C1-C6 alkyl, R3 represents H or C1-C6 alkyl, Y represents a bond or C1-C6 alkylene (straight or branched, optionally substituted with OH or CF3), R4 represents phenyl, hetero Represents a cyclic group selected from aryl4, heterocyclyl4 and C3-C6 cycloalkyl, wherein each cyclic group is halo, C1-C6 alkyl optionally substituted with 1 to 3 halogen atoms, phenyl, C1-C6 alkyl substituted with phenyl, C1-C6 alkoxy optionally substituted with 1 to 3 halogen atoms, cyano, heteroaryl 4a and heterocyclyl Optionally substituted with 1 to 3 substituents selected from benzene 4a, wherein each cyclic group is a benzene ring or a 5 or 6 membered heteroaromatic or heterocyclic ring (1 to 3 respectively). Optionally fused to a heteroatom (containing N, O and S) and each cyclic group is substituted, the substitution may generally occur anywhere in any fused ring system , And heterocyclyl 4 and heterocyclyl 4a may be ad
